Welcome to our dedicated page for Goodrx Holdings news (Ticker: GDRX), a resource for investors and traders seeking the latest updates and insights on Goodrx Holdings stock.
GoodRx Holdings, Inc. (NASDAQ: GDRX) is widely described as the leading platform for medication savings in the U.S., and its news flow reflects that role at the intersection of digital healthcare, pharmacy, and pharmaceutical manufacturers. Company announcements highlight new partnerships, product launches, and financial updates that shape how consumers, pharmacies, and manufacturers approach prescription affordability.
News about GoodRx often covers collaborations with major healthcare players. Examples include the RxSmartSaver program powered by GoodRx at national and regional retail pharmacies, which brings brand medication savings directly to the pharmacy counter, and an exclusive partnership with Surescripts that integrates GoodRx discounted cash prices into Script Corner, a patient experience product focused on prescription price transparency.
GoodRx also issues press releases on new consumer offerings and subscriptions. Recent updates describe GoodRx for Weight Loss, a telemedicine subscription for GLP-1 weight management treatment, and GoodRx for Hair Loss, a subscription program for men that combines virtual consultations, prescriptions for oral finasteride or oral minoxidil when appropriate, and discreet home delivery. Additional news highlights defined cash prices for medications such as Repatha, Ozempic, Wegovy, and the Wegovy pill at tens of thousands of pharmacies nationwide via GoodRx.
Investors and observers can also find earnings-related news, including quarterly financial results, guidance commentary, and participation in healthcare conferences. Together, these updates provide insight into GoodRx’s strategy across prescription transactions, subscriptions, pharma manufacturer solutions, and telehealth. For anyone tracking GDRX, this news page offers a focused view of how the company is evolving its platform, expanding partnerships, and addressing medication affordability across the U.S. healthcare system.
GoodRx (GDRX) has launched GoodRx Health, a platform providing research-based answers to health questions. This initiative aims to deliver concise, actionable knowledge through various tools including GoodRx Answers and award-winning videos. The platform is backed by an editorial team of doctors and pharmacists, focusing on areas like health knowledge, financial guidance, and trustworthy research. With nearly 20 million monthly users, GoodRx seeks to enhance consumer advocacy in healthcare decisions and capture a larger share of the $30 billion addressable market.
GoodRx Holdings (GDRX) will host a virtual educational webinar, GoodRx 101, for analysts and investors on September 30, 2021, at 11:30 a.m. PT (2:30 p.m. ET). The session will provide an overview of the company's business, though no new financial information will be disclosed. Participants can join via the webcast at investors.goodrx.com or use the dial-in number (833) 614-1447. An archived version of the presentation will be accessible for 30 days post-event.
GoodRx is a leading digital healthcare resource, having helped consumers save over $30 billion since its inception in 2011.
Summary not available.
Summary not available.
GoodRx Holdings (GDRX) announced its participation in three upcoming virtual investor conferences. The events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 11:00 a.m. PT, the Citi 2021 Global Technology Virtual Conference on September 14 at 9:10 a.m. PT, and the Goldman Sachs 30th Annual Communacopia Conference on September 22 at 11:55 a.m. PT. Live webcasts and archived recordings will be accessible on their Investor Relations website. GoodRx, a leader in healthcare savings, has helped Americans save over $30 billion since 2011.
GoodRx Holdings (GDRX) announced its second quarter 2021 financial results on August 12, with a conference call scheduled to discuss the outcomes and future outlook. The company claims to have saved Americans over $30 billion since 2011, providing affordable healthcare services like telehealth and lab tests. GoodRx emphasizes its role as America’s leading resource for healthcare savings.
Summary not available.
GoodRx, Inc. (Nasdaq: GDRX) and Boehringer Ingelheim have initiated a partnership to enhance access to copay programs for diabetes and COPD medications on the GoodRx platform. This collaboration aims to provide approximately $15 million in annual savings for patients in need of life-enhancing drugs. Diabetes impacts over 10% of the U.S. population, with medical costs considerably higher for affected individuals. With more patients facing increased financial burdens due to insurance changes, this initiative seeks to alleviate some of the cost barriers.
GoodRx (NASDAQ: GDRX) has formed a partnership with Surescripts to integrate drug discount pricing into Surescripts' Real-Time Prescription Benefit system. This collaboration aims to enhance prescription price transparency, particularly for uninsured patients and those lacking price information from their health plans. The initiative could lead to significant savings—up to 80%—on prescriptions, fostering better patient decision-making at the point of care. This effort aligns with GoodRx's mission to improve healthcare affordability for Americans.
GoodRx (NASDAQ: GDRX) recently published a consumer survey revealing its positive impact on pharmacy retailers. Key findings show that GoodRx enhances medication affordability, with 81% of users able to afford all prescriptions after using the service, compared to only 23% beforehand. Additionally, nearly 80% of users reported buying other items while picking up prescriptions, averaging $40 in extra purchases. The survey also indicated that 85% of participants were more likely to return to their pharmacy due to their positive experience with GoodRx, highlighting its role in boosting foot traffic and customer loyalty.
FAQ
What is the current stock price of Goodrx Holdings (GDRX)?
What is the market cap of Goodrx Holdings (GDRX)?
